Compile Data Set for Download or QSAR
Report error Found 666 for UniProtKB: P33534
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235787(US9359399, 1)
Affinity DataEC50:  0.0430nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235785(US9359399, 2 | CVD-0019439)
Affinity DataEC50:  0.0480nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235793(US9359399, 3)
Affinity DataEC50:  0.0520nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235783(US9359399, 4)
Affinity DataEC50:  0.0750nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235784(US9359399, 5)
Affinity DataEC50:  0.0340nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235794(US9359399, 6)
Affinity DataEC50:  0.0360nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235795(US9359399, 7)
Affinity DataEC50:  0.0120nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235796(US9359399, 8)
Affinity DataEC50:  0.0430nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235797(US9359399, 9)
Affinity DataEC50:  0.0780nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235798(US9359399, 10)
Affinity DataEC50:  0.826nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235799(US9359399, 11)
Affinity DataEC50:  0.0520nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235800(US9359399, 12)
Affinity DataEC50:  0.0550nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235786(US9359399, 13)
Affinity DataEC50:  0.0320nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235801(US9359399, 14)
Affinity DataEC50:  0.349nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235802(US9359399, 15)
Affinity DataEC50:  0.0280nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235803(US9359399, 16)
Affinity DataEC50:  0.0210nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235804(US9359399, 17)
Affinity DataEC50:  0.0390nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235805(US9359399, 18)
Affinity DataEC50:  1.02nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235806(US9359399, 19)
Affinity DataEC50:  2.15nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235808(US9359399, 20)
Affinity DataEC50:  0.491nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235807(US9359399, 21)
Affinity DataEC50:  0.732nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235809(US9359399, 22)
Affinity DataEC50:  0.0950nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235788(US9359399, 23)
Affinity DataEC50:  0.0910nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235810(US9359399, 24)
Affinity DataEC50:  0.0360nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235811(US9359399, 25)
Affinity DataEC50:  0.0314nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235812(US9359399, 26)
Affinity DataEC50:  0.0194nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235813(US9359399, 27)
Affinity DataEC50:  0.00560nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235789(US9359399, 28)
Affinity DataEC50:  0.0582nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235814(US9359399, 29)
Affinity DataEC50:  0.0464nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235790(US9359399, 30)
Affinity DataEC50:  0.129nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235815(US9359399, 31)
Affinity DataEC50:  0.0216nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235816(US9359399, 32)
Affinity DataEC50:  0.0485nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235791(US9359399, 33)
Affinity DataEC50:  0.0767nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235817(US9359399, 34)
Affinity DataEC50:  0.354nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235818(US9359399, 35)
Affinity DataEC50:  0.0359nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM235792(US9359399, 36)
Affinity DataEC50:  0.0234nMT: 2°CAssay Description:Mouse R1.G1 cells (ATCC, Manassas, Va.) were grown in suspension in high glucose-DMEM (Dulbecco's Modified Eagle's Medium, Cellgro, Herndon, Va.) con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM60212(SMR000058767 | NALTREXONE HYDROCHLORIDE | MLS00006...)
Affinity DataEC50:  0.810nMAssay Description:Agonist activity at mouse KOR expressed in CHO cells after 1.5 hrs by [35S]GTPgammaS binding assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2016
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50292919(17-Cyclopropylmethyl-3,14beta-dihydroxy-4,5r-epoxy...)
Affinity DataEC50:  11nMAssay Description:Agonist activity at mouse KOR expressed in CHO cells after 1.5 hrs by [35S]GTPgammaS binding assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2016
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50066348(CHEMBL3401554)
Affinity DataEC50:  63nMAssay Description:Agonist activity at mouse KOR expressed in CHO cells after 1.5 hrs by [35S]GTPgammaS binding assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2016
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50066279(CHEMBL2419121)
Affinity DataEC50:  26nMAssay Description:Partial agonist activity at mouse KOR expressed in CHO cells after 1.5 hrs by [35S]GTPgammaS binding assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2016
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM82551(C18130 | CAS_105618-26-6 | NORBNI | NOR-BNI (HCI)2)
Affinity DataKd:  1.65nMAssay Description:Displacement of [3H]U69,593 from kappa opioid receptor in mouse brain tissueMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/16/2012
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM21015([tyrosyl-3,5-3H(N)]-D-Ala2-Mephe4-glyol5-enkephali...)
Affinity DataEC50:  4.00E+3nMAssay Description:Agonist activity at mouse KOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50000092(Analog of 14-(Arylhydroxyamino)codeinone | 4-methy...)
Affinity DataEC50:  400nMAssay Description:Agonist activity at mouse KOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50493045(CHEMBL2418744)
Affinity DataEC50:  5.00E+4nMAssay Description:Agonist activity at mouse KOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50493046(CHEMBL2418745)
Affinity DataEC50:  1.00E+4nMAssay Description:Agonist activity at mouse KOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50493048(CHEMBL2418743)
Affinity DataEC50:  5.00E+4nMAssay Description:Agonist activity at mouse KOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50493047(CHEMBL2418738)
Affinity DataEC50:  3.20E+4nMAssay Description:Agonist activity at mouse KOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50493049(CHEMBL2418739)
Affinity DataEC50:  1.60E+3nMAssay Description:Agonist activity at mouse KOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50370595(US9233167, Oxycodone | Oxycontin | OXYCODONE | US1...)
Affinity DataEC50:  1.60E+4nMAssay Description:Agonist activity at mouse KOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
TargetKappa-type opioid receptor(Mouse)
Cara Therapeutics

US Patent
LigandPNGBDBM50493044(CHEMBL2418741)
Affinity DataEC50:  1.59E+5nMAssay Description:Agonist activity at mouse KOR assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by cell based TR-FRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2020
Entry Details Article
PubMed
Displayed 1 to 50 (of 666 total ) | Next | Last >>
Jump to: